Results 41 to 50 of about 56,243 (346)

Evidence and Extrapolation: Mechanisms for Regulating Off-Label Uses of Drugs and Devices [PDF]

open access: yes, 2014
A recurring, foundational issue for evidence-based regulation is deciding whether to extend governmental approval from an existing use with sufficient current evidence of safety and efficacy to a novel use for which such evidence is currently lacking ...
Abbott, Ryan, Ayres, Ian
core   +3 more sources

Direct and Indirect Drug Design Approaches for the Development of Novel Tricyclic Antipsychotics: Potential 5-HT2A Antagonist

open access: yesJournal of Chemistry, 2013
Schizophrenia is a mental disorder manifested largely by disintegration of thought processes and emotional responsiveness. Given the therapeutic and toxic limitations of clinically available drugs, it is clear that there is still a need for the ...
Mahantesh Namdev Jadhav   +3 more
doaj   +1 more source

QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy

open access: yesAnnals of General Psychiatry, 2005
Background Several antipsychotic agents are known to prolong the QT interval in a dose dependent manner. Corrected QT interval (QTc) exceeding a threshold value of 450 ms may be associated with an increased risk of life threatening arrhythmias ...
Piccinelli Marco   +9 more
doaj   +1 more source

Effects of intervention with the SAFE strategy on trachoma across Ethiopia.

open access: yes, 2011
BACKGROUND/AIMS: The impact of the SAFE strategy (surgery, antibiotics, face washing, environmental hygiene), recommended to eliminate blinding trachoma, is not well explored.
Patel, D   +3 more
core   +1 more source

Osteocyte-Driven Downregulation of Snail Restrains Effects of Drd2 Inhibitors on Mammary Tumor Cells [PDF]

open access: yes, 2018
While bone is a frequent target of breast cancer-associated metastasis, little is known about the effects of tumor-bone interactions on the efficacy of tumor-suppressing agents.
Chen, Andy   +8 more
core   +1 more source

Assessment of adherence to treatment with injectable extended-release antipsychotics within a pharmacotherapeutic follow-up program [PDF]

open access: yesFarmacia Hospitalaria, 2019
Objective: To describe an injectable extended-release antipsychotic pharmacotherapeutic follow-up program and to assess adherence among patients included in the program.
Carmen Gallastegui   +5 more
doaj   +1 more source

Aripiprazole-induced writer’s cramp: a case report

open access: yesOpen Journal of Psychiatry and Allied Sciences, 2016
Dystonia is a movement disorder, which causes sustained muscle contractions, twisting movements, and abnormal postures. Writer’s cramp is the most commonly identified tasks-specific focal dystonia of writing, characterised by abnormal muscle spasm of ...
Priyajyoti Chakma, Punyadhar Das
doaj   +1 more source

Dosing strategies for switching from oral risperidone to paliperidone palmitate: Effects on clinical outcomes. [PDF]

open access: yes, 2017
IntroductionThere are currently no guidelines for switching patients from oral risperidone to paliperidone palmitate (Invega Sustenna®). Furthermore, the paliperidone long-acting injectable (LAI) package insert does not recommend bridging with oral ...
Hsia, Stephanie L   +4 more
core   +2 more sources

Repurposing the Antipsychotic Trifluoperazine as an Antimetastasis Agent [PDF]

open access: yesMolecular Pharmacology, 2015
Because cancer cell invasion is a critical determinant of metastasis, targeting invasion is a viable approach to prevent metastasis. Utilizing a novel three-dimensional high-throughput invasion assay, we screened a National Cancer Institute compound library and discovered compounds demonstrating inhibitory effects on cancer cell invasion.
Basil Rigas   +7 more
openaire   +2 more sources

Reservoir‐Type Subcutaneous Implantable Devices Containing Porous Rate Controlling Membranes for Sustained Delivery of Risperidone

open access: yesAdvanced Healthcare Materials, EarlyView.
This study presents a novel implantable drug delivery systemwith a biodegradable poly(caprolactone) membrane and compressed drug core forsustained release. These implantable devices deliver risperidone in vitro for 170 days and in vivo for 49 days in rats, showing promise for chronic conditions like schizophrenia.
Linlin Li   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy